I

India Globalization Capital
D

IGC

0.38800
USD
0.00
(0.52%)
مغلق
حجم التداول
1,400
الربح لكل سهم
0
العائد الربحي
0
P/E
-2
حجم السوق
29,346,931
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACB
    -0.08000
    (-1.30%)
    6.06000 USD
    C
    CGC
    -0.82500
    (-10.86%)
    6.77500 USD
    C
    CRON
    -0.11000
    (-4.49%)
    2.34000 USD
    H
    HEXO
    -0.03000
    (-2.36%)
    1.23000 USD
    O
    OGI
    -0.12000
    (-7.14%)
    1.56000 USD
    S
    SNDL
    -0.07000
    (-3.08%)
    2.20000 USD
    T
    TLRY
    -0.03500
    (-1.73%)
    1.98500 USD
    V
    VFF
    -0.04000
    (-3.54%)
    1.09000 USD
    المزيد
الأخبار
المقالات

العنوان: IGC Pharma

القطاع: Healthcare
الصناعة: Biotechnology
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.